MedTrace Logo

Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)

NCT00705666 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 789

Last updated 2015-10-02

Study results available
· View outcomes & findings →

Summary

In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy. Three years after these recommendations, it is of interest to understand the evolution of hepatitis C management in France in real clinical practice. This observational study will permit the identification of patients who are treated and will provide information on the use of PegIntron/ Ribavirin.

Conditions

  • Hepatitis C, Chronic
  • Hepacivirus

Interventions

BIOLOGICAL

Peginterferon alfa-2b (SCH 54031)

Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.

DRUG

Ribavirin (SCH 18908)

Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-07-31
Completion
2008-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705666 on ClinicalTrials.gov